Germany’s BioNTech, which developed a coronavirus vaccine with US giant Pfizer in record time, said on Monday that it aimed to start trialling a malaria vaccine next year using the same breakthrough mRNA technology. The AFP news agency reports that the company said it will assess several vaccine candidates and begin clinical trials by the end of 2022 while it is also looking at setting up an mRNA hub in Africa so that future vaccines can be manufactured and distributed on the continent. If successful, the vaccine could be a crucial step in the fight against the mosquito-borne disease, which kills more than 400,000 people a year — mainly young children in Africa.